Research shows that remodulating tumor hypoxia can facilitate cancer immunotherapy by stimulating anti-tumor T cells and NK cells, reducing macrophage recruitment and PD-L1 on cancer cells, and maintaining M1-TAMs polarization [179,180]. The gene discussed is CD274; the disease is cancer.